The FDA recently approved Merck's Keytruda and Keytruda Qlex combined with Welireg for treating earlier-stage clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. This drug combination contributed to $8.23 billion in sales for Merck in Q1, marking a 12.1% increase year-over-year. Looking ahead, the second half of 2026 is expected to bring several catalysts for Merck, supported by ongoing research and development achievements. This approval and strong sales growth highlight Merck's promising risk/reward profile for investors.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biolog...
The global OLED display market is projected to grow from $51.84 billion in 2025 to $163.19 billion by 2035, with a CAGR of 13.7%. Growth is fueled by expanding OLED use in smartphones, laptops, automotive displays, and premium consumer electronics du...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
The Schwab U.S. Dividend Equity ETF (SCHD) provides investors with a low-cost, diversified portfolio of U.S. companies known for consistent dividend growth, making it an attractive option for those seeking a stable and growing income stream in retire...
